Pfizer

PFE

New York, United States· Est. 1849

pfizer.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

PFE · Stock Price

USD 26.48+4.20 (+18.85%)

Market Cap: $147.6B

Historical price data

Market Cap: $147.6BPipeline: 200 drugsPatents: 20Founded: 1849Employees: 80,000+HQ: New York, United States

Sector Ranking#47 in Small Molecule Drugs #32 in Biologics / Biosimilars

Overview

Pfizer's mission is to deliver 'Breakthroughs that change patients' lives' through scientific innovation across a diversified portfolio of therapeutics and vaccines. Its strategic achievements include the rapid development and global commercialization of the COVID-19 vaccine Comirnaty, establishing a leading mRNA platform, and a disciplined pipeline expansion into high-growth areas like obesity and oncology. The company's strategy focuses on sharpening its R&D focus on transformative science, optimizing its cost structure, and deploying capital for strategic business development to drive long-term growth post-pandemic.

Internal MedicineOncologyVaccinesInflammation & ImmunologyRare Disease

Technology Platform

A diversified platform spanning validated mRNA vaccine technology, advanced biologics and biosimilars manufacturing, small molecule discovery, and integrated computational/AI-driven drug discovery.

Pipeline

200

200 drugs in pipeline

Drug	Indication	Stage
pregabalin (Lyrica) + pregabalin (Lyrica) + pregabalin (Lyri...	Epilepsy	Pre-clinical
Tacrolimus + Sirolimus + Mycophenolate Mofetil + Prednisone	Polycystic Liver Disease	Pre-clinical
Amlodipine/Atorvastatin	Hypertension	Pre-clinical
etanercept (Enbrel®)	Psoriasis	Pre-clinical
Talazoparib	Breast Cancer	Pre-clinical

FDA Approved Drugs

HYMPAVZIBLAOct 11, 2024

TALZENNANDAMar 7, 2024

VELSIPITYNDAOct 12, 2023

Opportunities

Pfizer's most significant near-term opportunities lie in capturing market share in the massive obesity pharmacotherapy market with its GLP-1 candidates and leveraging its Seagen acquisition to build a leading, diversified oncology franchise centered on antibody-drug conjugates.

The expansion of its mRNA platform into seasonal influenza and other infectious diseases represents a major long-term growth vector.

Risk Factors

Key risks include clinical or commercial failure of high-stakes late-stage pipeline assets (particularly in obesity), inability to fully offset looming patent expirations on major drugs, and execution risks associated with integrating large acquisitions like Seagen.

Macro risks include sustained pricing pressure and regulatory hurdles.

Competitive Landscape

Pfizer competes directly with other pharmaceutical giants across all its core areas: against Novo Nordisk and Eli Lilly in obesity/diabetes, against Merck, Bristol Myers Squibb, and Roche in oncology, and against GSK, Moderna, and Sanofi in vaccines. Its scale and integrated platform are key differentiators in this intense competitive environment.